Clinical trial of salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of chronic obstructive pulmonary disease
10.13699/j.cnki.1001-6821.2017.11.002
- VernacularTitle:沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的临床研究
- Author:
Yu-Ling SUI
1
;
Xue-Tang LI
;
Yu-Cai LIU
;
Yan-Li GAO
;
Yong-Feng WANG
Author Information
1. 临沂市沂水中心医院
- Keywords:
salmeterol xinafoate and fluticasone propionate;
chronic obstructive pulmonary disease;
tiotropium bromide powder inhalation;
forced vital capacity
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(11):966-969
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of salmeterol xinafoate/ fluticasone propionate in the treatment of chronic obstructive pulmonary disease(COPD).Methods A total of 70 patients with COPD were randomly divided into control group and treatment group,35 cases in each group.Patients in the two groups were all given regular treatment.Patients in the control group were given inhalation treatment with 18 μg tiotropium bromide powder inhalation,qd.Patients in the treatment group were given 50 μg salmeterol fluticasone propionate powder,qd.Patients in the two groups were treated for three cycles (28 days per cycle).The clinical efficacy,pre-and post-treatment of forced vital capacity (FVC),one second forced expiratory volume (FEV1),peak expiratory flow rate value(PEF),FEV1 / FVC,the predicted percentage of FEV1 and PEF value,St.George Hospital Respiratory Questionnaire (SGRQ),multi factor grading system (BODE:body mass index,airflow obstruction,dyspnea and exercise capacity) index score and the incidence of adverse reaction were compared between the two groups.Results After treatment,the total clinical effective rates in the treatment group and the control group were 91.43％ (32/35 cases) and 77.14％ (27/35 cases),respectively,with statistically significant difference (P＜0.05).After treatment,the FEV1 in the treatment group and the control group were(1.86 ± 0.19)L and (1.42 ± 0.17) L,respectively.The FEV1/FVC were (42.93 ± 4.25) ％ and (39.73 ± 3.68) ％,respectively.The PEF were (3.69 ±0.37)L and(3.11 ±0.35)L,respectively.The FEV1/Predicted value were(48.57 ±4.97)％ and (44.47 ±4.51)％,respectively.The PEF/ Predicted value were (48.92 ±5.05)％ and (41.53 ± 4.55)％,respectively.The SGBQ score were (44.97 ±4.96) and (42.01 ±4.67) points,respectively.The BODE score were (5.98 ±0.59) and (5.67 ± 0.59) points.There were statistically significant differences in all the items above between the two groups(P ＜ 0.05).The adverse drug reactions in the treatment group were headache (1 case),tremor (1 case) and palpitation (1 case),while headache(2 cases),tremor(1 case) and hoarseness(2 cases) were found in the control group.The rates of adverse drug reaction in the treatment group and the control group were 8.57％ (3/35 cases) and 14.29％ (5/35 cases) respectively,and no statistical significance was found (P ＞ 0.05).Conclusion Salmeterol xinafoate/fluticasone propionate was safe and effective in the clinical treatment of COPD.
